Literature DB >> 8958922

Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses.

B L Kelsall1, E Stüber, M Neurath, W Strober.   

Abstract

Recent studies have demonstrated that the treatment of mice with anti-gp39 antibodies impairs T-cell functions in the murine collagen type II-induced arthritis model, in acute semi-allogenic graft-versus-host disease, and in the allo-specific CTL-reaction, that is, reactions that are believed to be mediated by Th1-type T cells. On the other hand, the administration of anti-gp39 antibody did not influence Th2 T-cells responses, suggesting that CD40-CD40L interactions are more crucial for Th1 than Th2 T-cell development. Recent studies also demonstrate that dendritic cells (DC) are capable of driving a Th1 T-cell response that is mediated by IL-12. In addition, stimulation of CD40 on human monocytes results in IL-12 production, suggesting that activated T cells expressing CD40L may directly induce the production of IL-12 by antigen-presenting cells, thus allowing for the generation of a Th1 T-cell response in the absence of intracellular pathogens. We investigated whether the CD40-CD40L interaction was important in the production of IL-12 by DCs in an in vitro system that allowed precise control of cytokine concentrations. Initially we showed that FACS-purified mouse spleen DCs produce high amounts of IL-12 p40 in response to CD40 crosslinking by CD40L-expressing fibroblasts. We then demonstrate that DCs also produce IL-12 p40 in a more physiologic system using purified DCs pulsed with ovalbumin (OVA) and then cultured with LECAM-1hi T cells from ovalbumin T-cell receptor transgenic mice. Finally, we show that IL-10 has a potent capacity to shut down CD40-induced IL-12 p40 secretion; and, in addition, IL-4 partially inhibits CD40-induced IL-12 p40 secretion and enhances IL-10-mediated inhibition in an additive fashion. We also investigated the in vivo relevance of this interaction in an experimental model for a Th1-mediated disease, the hapten reagent (TNBS)-induced colitis. The administration of anti-gp39 (CD40L) antibodies during the induction phase of the Th1 response completely prevented IFN-gamma production by CD4 T cells from the intestinal lamina propria and also the clinical and histological evidence of disease. In further studies we showed that the prevention of disease activity was due to an inhibition of IL-12 secretion. Thus, the injection of recombinant IL12 p75 heterodimer into TNBS + anti-gp39-treated mice reversed the effect of anti-gp39 and resulted in severe disease activity. In conclusion, these findings suggest that DCs produce IL-12 in response to CD40 signaling, that a mechanism by which IL-4 may induce Th2 development is by acting with IL-10 to inhibit IL-12 production by DCs, and that the CD40L-CD40 interaction is crucial for the IL-12-dependent priming of Th1 T cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958922     DOI: 10.1111/j.1749-6632.1996.tb52660.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  42 in total

1.  Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies.

Authors:  Naoya Inoue; Mikio Watanabe; Hiroya Yamada; Kazuya Takemura; Fumiaki Hayashi; Noriko Yamakawa; Maiko Akahane; Yu Shimizuishi; Yoh Hidaka; Yoshinori Iwatani
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

2.  Isolation and partial purification of macrophage- and dendritic cell-activating components from Mycoplasma arthritidis: association with organism virulence and involvement with Toll-like receptor 2.

Authors:  Barry C Cole; Hong-Hua Mu; Nathan D Pennock; Akira Hasebe; Fok V Chan; Leigh R Washburn; Morgan R Peltier
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Mechanisms by which chronic ethanol feeding limits the ability of dendritic cells to stimulate T-cell proliferation.

Authors:  Ji Fan; Michelle R Edsen-Moore; Lucas E Turner; Robert T Cook; Kevin L Legge; Thomas J Waldschmidt; Annette J Schlueter
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

4.  Characterization of colonic dendritic cells in normal and colitic mice.

Authors:  Sheena M Cruickshank; Nicholas R English; Peter J Felsburg; Simon R Carding
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

5.  Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.

Authors:  A Escobar; M López; A Serrano; M Ramirez; C Pérez; A Aguirre; R González; J Alfaro; M Larrondo; M Fodor; C Ferrada; F Salazar-Onfray
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

6.  CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals.

Authors:  Matthew W Auten; Weitao Huang; Guixiang Dai; Alistair J Ramsay
Journal:  Vaccine       Date:  2012-02-18       Impact factor: 3.641

7.  Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages.

Authors:  G Chen; P A Darrah; D M Mosser
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Interleukin-12 is necessary for the priming of CD4+ T cells required during the elicitation of HIV-1 gp120-specific cytotoxic T-lymphocyte function.

Authors:  Shalini Gupta; Ramanamurthy Boppana; Gyan C Mishra; Bhaskar Saha; Debashis Mitra
Journal:  Immunology       Date:  2008-02-20       Impact factor: 7.397

9.  Levels of CD40 expression on dendritic cells dictate tumour growth or regression.

Authors:  G Murugaiyan; S Martin; B Saha
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

10.  Impaired CD40-signalling in Langerhans' cells from murine neonatal draining lymph nodes: implications for neonatally induced cutaneous tolerance.

Authors:  C C Simpson; G M Woods; H K Muller
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.